LINCOLN PHARMACEUTICALS

BSE: 531633 28 Jun 2025

Healthcare

₹ 556.8

Lincoln Pharmaceuticals ltd. specializes in Pharmaceuticals within the Healthcare sector.

LINCOLN PHARMACEUTICALS

BSE: 531633 28 Jun 2025

Healthcare

₹ 556.8

Lincoln Pharmaceuticals ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

335.0

Dividend Yield

0.32%

Debt to Equity

0.0

Stock P/E

13.7

Market Cap

1,131 Cr

LINCOLN PHARMACEUTICALS - Share Price & Details

Market Cap

₹1,131

High /Low

980.0 / 499.0

Stock P/E

13.7

Book Value

₹335.0

Dividend Yield

0.32

ROCE

17.6

ROE

₹13.0

Face Value

10.0

PEG Ratio

1.39

EVEBITDA

₹8.94

Debt

0.00

CMP / FCF

27.5

Debt to equity

₹0.0

NP Ann

82.4

High price all time

980.0

Piotroski score

₹7.0

Graham Number

557.0

No. Eq. Shares

2.0

Net CF

₹7.67

Net profit

82.4

Price to book value

1.68

Interest Coverage

₹59.1

Low price all time

14.8

Industry PE

32.7

Reserves

₹652

Free Cash Flow

₹73.9

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
LOOKS HEALTH SERVICES LIMITED	NA	NA	NA	NA	5.11	256.0
Triochem Products Ltd.,	NA	NA	NA	NA	0
LINCOLN PHARMACEUTICALS LTD.	1613.03	115.75	1681.83	5.78	1,131	13.7
KMC SPECIALITY HOSPITALS (INDI	NA	NA	NA	NA	1073	50.1
Kwality Pharmaceuticals Limite	NA	NA	NA	NA	1071	26.9

Peer Comparison Chart

About LINCOLN PHARMACEUTICALS

Lincoln Pharmaceuticals ltd., with Security Code 531633, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	133.8	112.5	135.6	156.0	146.4	142.5	147.3	161.2	146.6	168.2
Expenses	107.0	95.9	114.9	124.8	116.8	124.1	124.6	132.8	122.9	141.5
Operating Profit	26.8	16.6	20.7	31.1	29.7	18.4	22.7	28.4	23.7	26.7
OPM %	20%	14.76%	15.28%	19.97%	20.25%	12.9%	15.43%	17.6%	16.15%	15.89%
Other Income	6.4	3.9	7.7	8.7	11.0	7.0	10.4	10.0	9.0	-6.9
Interest	0.3	1.1	0.4	0.4	0.2	0.5	0.4	0.3	0.7	0.4
Depreciation	2.3	2.4	2.5	2.6	2.8	2.7	3.2	3.2	3.2	3.2
Profit before tax	30.5	17.0	25.4	36.9	37.7	22.2	29.5	34.8	28.7	16.2
Tax %	-29.2%	-26%	-25.3%	-25%	-25.6%	-16.3%	-19.7%	24.3%	-27.6%	28.8%
Net Profit	21.6	12.6	19.0	27.7	28.0	18.6	23.7	26.3	20.8	11.6
EPS in Rs	10.79	6.27	9.49	13.81	14	9.28	11.82	13.15	10.37	5.78

Metrics	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	140.6	133.8	112.5	135.6	156.0	146.4	142.5	147.3	161.2	146.6
Expenses	111.7	107.0	95.8	114.9	124.8	116.8	124.1	124.6	132.8	122.9
Operating Profit	28.9	26.8	16.6	20.7	31.1	29.7	18.4	22.7	28.4	23.7
OPM %	20.55%	20%	14.8%	15.28%	19.97%	20.25%	12.9%	15.43%	17.6%	16.15%
Other Income	5.7	6.4	3.9	7.7	8.7	11.0	7.0	10.4	10.0	9.0
Interest	0.1	0.3	1.1	0.4	0.4	0.2	0.5	0.4	0.3	0.7
Depreciation	2.4	2.3	2.4	2.5	2.6	2.8	2.7	3.2	3.2	3.2
Profit before tax	32.1	30.5	17.0	25.4	36.9	37.7	22.2	29.5	34.8	28.7
Tax %	-26%	-29.2%	-26%	-25.3%	-25%	-25.6%	-16.3%	19.7%	-24.3%	27.6%
Net Profit	23.7	21.6	12.6	19.0	27.7	28.0	18.6	23.7	26.3	20.8
EPS in Rs	11.84	10.79	6.27	9.49	13.81	14	9.28	11.82	13.15	10.37

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	11%
5 Years:	11%
3 Years:	10%
TTM:	7%

Compounded Profit Growth
10 Years:	19%
5 Years:	11%
3 Years:	6%
TTM:	-11%

Stock Price CAGR
10 Years:	21%
5 Years:	28%
3 Years:	25%
1 Year:	-3%

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	10%
TTM:	7%

Compounded Profit Growth
10 Years:	19%
5 Years:	10%
3 Years:	6%
TTM:	-11%

Stock Price CAGR
10 Years:	21%
5 Years:	28%
3 Years:	25%
1 Year:	-3%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

LINCOLN PHARMACEUTICALS

LINCOLN PHARMACEUTICALS

LINCOLN PHARMACEUTICALS - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About LINCOLN PHARMACEUTICALS

Latest News

Who are in the management team of Lincoln Pharma.?

How has been the historical performance of the Lincoln Pharma.?

Lincoln Pharma Sets ₹1,000 Crore Revenue Goal Within Three Years

Lincoln Pharmaceuticals targets ₹1000 crore revenues in next 3 years

Q4 Results

Lincoln Pharma posts Rs 11.62 cr profit for Jan-Mar; revenue at Rs 161 cr

Lincoln Pharmaceuticals Faces Significant Stock Decline Amid Broader Market Challenges

Lincoln Pharmaceuticals consolidated net profit declines 37.74% in the March 2025 quarter

Lincoln Pharmaceuticals Reports Mixed Financial Results Amid Growth and Challenges in March 2025

Lincoln Pharmaceuticals Faces Continued Decline Amid Broader Market Challenges

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) largest shareholder, Senior Key Executive Munjal Patel sees holdings value fall by 16% following recent drop

Lincoln Pharma reports standalone net profit of Rs 20.77 Cr in Q3 FY25

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 20.77 crore in Q3 FY25

Investors Don't See Light At End Of Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Tunnel And Push Stock Down 28%

Lincoln Pharmaceuticals Faces Declining Profits Amidst Challenging Market Conditions in September 2023

NCLT Warrants Merger Of Lincoln Parenteral & Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Faces Significant Stock Volatility Amid Broader Market Stability in February 2025

Lincoln Pharmaceuticals consolidated net profit declines 25.93% in the December 2024 quarter

Lincoln Pharmaceuticals Gains 7.83% on December 30, Outperforming Sector by 1.71%

Insider Returns Down To ₹16m As Lincoln Pharmaceuticals' Stock Dips 13%

Lincoln Pharmaceuticals Stock Declines 7.09% on December 18, 2024

Lincoln Pharmaceuticals Hits 52-Week High, Outperforms Sector and Market

Lincoln Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

723 BSE smallcap stocks end positive in the week gone by; Lincoln Pharma, HEG shine

Lincoln Pharmaceuticals' Stock Price Soars, Outperforms Sector and Sensex

Lincoln Pharmaceuticals Reaches All-Time High, Outperforms Sector and Sensex

Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified

Lincoln Pharmaceuticals Hits 52-Week High, Outperforms Sector with Strong Performance

Lincoln Pharmaceuticals' Stock Soars 9.67%, Outperforms Sector and Sensex

Debt-free small-cap stock Lincoln Pharma hits a lifetime high, rises over 30% in December

Lincoln Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

Debt-free small-cap stock Lincoln Pharma hits 20% upper circuit and a lifetime high; should you buy? | Stock Market News

Debt-free small-cap stock Lincoln Pharma hits 20% upper circuit and a lifetime high; should you buy?

Debt-Free Pharma Stock Locked At 20% Upper Circuit, FII & DII Raise Stake In Q2; Do You Own?

The stock of this Pharma Company Hits 20 per cent Upper Circuit with High Intraday Volumes; FIIs Increased their Stake in Q2 FY25

Lincoln Pharma Consolidated September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y

Lincoln Pharma Standalone September 2024 Net Sales at Rs 161.21 crore, up 3.35% Y-o-Y

Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Are Of Questionable Quality

Lincoln Pharmaceuticals Upgraded to 'Hold' Rating by MarketsMOJO, Attractive Valuation and Institutional Investor Confidence Boost Stock

Lincoln Pharmaceuticals consolidated net profit declines 4.77% in the September 2024 quarter

Lincoln Pharmaceuticals Ltd reports Net Profit of Rs. 50.03 crore in H1 FY25, growth of 7.55 Percent Y-o-Y

MarketsMOJO Downgrades Lincoln Pharmaceuticals to 'Sell' Due to Poor Growth and Bearish Trend

Lincoln Pharmaceuticals' Stock Reaches 52-Week High, Outperforms Sector and Sensex

Be Sure To Check Out Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Before It Goes Ex-Dividend

Lincoln Pharmaceuticals' Stock Reaches All-Time High, Outperforms Sector with 'Hold' Call from MarketsMOJO

Lincoln Pharmaceuticals' Stock Reaches All-Time High, Outperforms Sector and Sensex

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be Increased To ₹1.80

Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?

Lincoln Pharmaceuticals' Stock Price Soars 9.22% on Strong Performance in Pharmaceutical Industry

Lincoln Pharma Consolidated June 2024 Net Sales at Rs 147.28 crore, up 8.6% Y-o-Y

Q1 Results, Aug 8: RVNL, LIC, MRF, IRCON International, Eicher Motors To Declare Earnings Today

Lincoln Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024

Lincoln Pharma Standalone June 2024 Net Sales at Rs 147.28 crore, up 8.6% Y-o-Y

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 23.67 crore in Q1FY25, growth of 24.51 % Y-o-Y

Lincoln Pharmaceuticals First Quarter 2025 Earnings: EPS: ₹11.82 (vs ₹9.49 in 1Q 2024)

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 23.67 crore in Q1 FY25, growth of 24.51 Percent Y-o-Y

Lincoln Pharma profit jumps 24pc to Rs 23.67cr in Apr-Jun

Lincoln Pharma Q1 profit up 24%

Lincoln Pharmaceuticals consolidated net profit rises 24.51% in the June 2024 quarter

Stock jumps 5% after company’s net profit increases by 27% QoQ

This Pharma Company Reports 25 per cent Profit Growth: Aiming for Rs 750 Crore Revenue by FY26, Promoter and FIIs Increased their Stake

Lincoln Pharma Profit Soars 24% in Q1 FY25 | Rs 23.67cr

Latest News | Lincoln Pharma Profit Jumps 24pc to Rs 23.67cr in Apr-Jun

Lincoln Pharma Q1FY25 results: Net profit jumps 24% to Rs 23.67cr

Lincoln Pharmaceuticals’s net profit increases by 24% YoY | Tap to know more | Inshorts

Lincoln Pharmaceuticals Receives 'Buy' Rating from MarketsMOJO, Shows Strong Financials and Performance

Jain Saabs GEMS : Why did Sandeep Jain choose Lincoln Pharmaceuticals Ltd today?

Pharma stock hits 20% upper circuit after receiving order worth ₹ 17.13 Cr from Rajasthan Medical Corporation

Munjal Patel Bought 1.3% More Shares In Lincoln Pharmaceuticals

Lincoln Pharma Consolidated March 2024 Net Sales at Rs 142.49 crore, up 26.71% Y-o-Y

Lincoln Pharma net rises 29% to ₹93.37cr in FY24